factors like time on dialysis prior to transplantation, graft function, and side effects of immunosuppressive drugs. Thus, the more time on dialysis prior to renal transplant and the lower renal allograft function, the higher is cardiovascular mortality after renal transplant. 4 Hypertension is one of the major "traditional" risk factors. In the general, population about 50% of stroke and ischemic heart disease worldwide are attributable to high blood pressure. 6 Hypertension affects about one third of the adult general population. The prevalence is even higher in renal transplant recipients. In this population, it affects the vast majority of patients. 7 Posttransplant, blood pressure is increased due to several mechanisms including impaired renal function, increased arterial stiffness, and immunosuppressive medication with calcineurin inhibitors and steroids. Hypertension is associated with an impairment of both patient and graft survival. 8, 9 Thus, blood pressure control is a cornerstone of follow-up care after renal transplantation.
For decades, blood pressure control focused almost exclusively on the mean or "usual" blood pressure, which was regarded as the main determinant of blood pressure-related vascular risk ("usual blood pressure hypothesis"). In recent years, there has been increasing evidence that the variability of systolic blood pressure constitutes an additional independent cardiovascular risk factor. [10] [11] [12] In the NHANES III population, it was demonstrated that the all-cause mortality was >50% greater in subjects with a standard deviation of inter-visit blood pressure >5 mm Hg independent of the underlying medication. 13 In 2010, a post hoc analysis of six studies including the ASCOT trial attracted considerable attention: Variability of systolic blood pressure proved to be a strong predictor of stroke, independent of mean systolic blood pressure. 14 Current hypertension guidelines describe the cardiovascular risk of blood pressure variability and therefore recommend ambulatory blood pressure measurement. [15] [16] [17] [18] To date, there are no data on the impact of blood pressure variability on mortality and graft survival after renal transplantation.
We performed a retrospective analysis of 887 subjects, who received a renal allograft at Charité-Universitätsmedizin Berlin or the University Hospital in Bochum, Germany, between 1997 and 2011
with a follow-up of up to 120 months after transplantation.
| ME THODS

| Study design and protocol
Patients who underwent kidney transplantation at two transplant centers at Charité-Universitätsmedizin Berlin, Germany (Charité- (GraphPad Software, La Jolla, CA, USA).
| Statistical analysis
| RE SULTS
A total of 877 subjects were included in the study according to the above-mentioned criteria. Ninety-six patients had <3 documented
blood pressure values and were excluded from further analysis.
Finally, 781 patients were divided into two groups based on the CV. A total of 226 (28.9%) patients had only three measurements (mean follow-up of these subjects 57.7 ± 33.8 months). Table 1 presents epidemiological and transplant-related data. Mean age of the study population was 50.1 ± 13.0 years. The most frequent cause of end-stage renal disease was glomerulonephritis (37.5%). A minority (13.7%) were live donor transplantations (Table 1) . Seventeen patients had been already transplanted in the past (re-transplants).
Patients were followed up for a maximum of 120 months with a mean follow-up of 78.1 ± 34.7 months. Mean eGFR 12 months after transplantation was 41.2 ± 19.5 mL/min. As described in Table 2 , the most frequent immunosuppressive regimen was a triple therapy TA B L E 2 Medication of study population F I G U R E 1 Patient and graft survival (composite endpoint) stratified according to systolic blood pressure (BP), systolic blood pressure variability as measured by the coefficient of variation (CV) and pulse pressure. Analysis was performed for two groups based on the median value of the parameter (BP, CV, pulse pressure) over a period of 120 mo. A, Kaplan-Meier curves. B, Cox regression curves adjusted for age, gender, BMI, and coronary heart disease were performed for those subjects with lower vs higher than median blood pressure variability. As presented in Table 1 , the group with lower CV had a slightly but significant higher body mass index (P = 0.03) but less frequently coronary artery disease (P = 0.04). Cox regression analysis for the composite endpoint showed a survival benefit for those subjects without coronary artery disease (P = 0.015). Therefore, in the following Cox regression analyses data were not only adjusted for age and gender but also for coronary heart disease and body mass index (BMI).
In a first Cox regression analysis, patient and graft survival were compared between transplant recipients with a CV <6.97% vs ≥6.98% after adjustment for the above-mentioned parameters.
Neither Kaplan-Meier nor Cox regression analysis revealed a difference in the composite endpoint of patient and graft survival between subjects with lower or higher long-term blood pressure variability (Figure 1A ,B; P = 0.45 and P = 0.17 respectively). In contrast, systolic blood pressure itself had an effect on the composite endpoint. Patients with systolic blood pressure under the median showed a significantly better outcome during the follow-up period than subjects with higher blood pressure in both Kaplan-Meier and Cox regression analyses (P < 0.001 and P = 0.001, Figure 1A,B) . Moreover, subjects with a lower pulse pressure had a higher cumulative survival in Kaplan-Meier analysis than those with higher pulse pressure (P < 0.001, Figure 1A ).
This effect did not persist after adjustment for age, gender, BMI, and coronary heart disease in Cox regression analysis (P = 0.49, Figure 1B ).
In a second analysis, we investigated whether the blood pressure variability in the first year after transplantation ("early blood pressure variability") predicted patient or graft outcome over the 10-year follow-up period. Median CV was 5.62% in this time. The corresponding Cox regression analyses were adjusted for age, gender, coronary artery disease, and BMI in the same manner as for blood pressure variability over the overall follow-up period. Both Kaplan-Meier and
Cox regression analyses showed a numeric trend for a better outcome with lower blood pressure variability without reaching significance (P = 0.22 and P = 0.27, respectively; Figure 2A ,B). In analogy to the first analysis, a lower systolic blood pressure was associated with higher patient and graft survival (P < 0.001 and P = 0.003, respectively; Figure 2A ,B). A lower pulse pressure was associated with a higher cumulative patient and graft survival in Kaplan-Meier analysis (P < 0.001, Figure 2A ). This association did not persist, however, F I G U R E 2 Patient and graft survival (composite endpoint) stratified according to systolic blood pressure (BP), systolic blood pressure variability as measured by the coefficient of variation (CV) and pulse pressure. Analysis was performed for two groups based on the median value of the parameter (BP, CV, pulse pressure) over the first 12 mo after transplantation. A, Kaplan-Meier curves. B, Cox regression curves adjusted for age, gender, BMI, and coronary heart disease after adjustment for age, gender, BMI, and coronary heart disease in Cox regression analysis (P = 0.76, Figure 2B ).
Finally, Cox regression analyses were performed separately for patient and graft survival. As presented in Figure 3 , a lower systolic blood pressure was associated with 87% cumulative patient survival (P = 0.017 Figure 3A ) and 82% graft survival (P = 0.05, Figure 3B ).
Blood pressure variability was neither associated with patient nor with graft survival (P = 0.10 and P = 0.95, respectively; Figure 3A ,B).
Pulse pressure showed a significant association with patient but not with graft survival (P = 0.001 and P = 0.11, respectively; Figure 3A ,B). Systolic blood pressure at 12 months was negatively associated with eGFR at 12 months in linear regression analysis (P < 0.001, r = −0.29). Systolic CV, however, did not correlate with eGFR at 12 months (P = 0.16, r = 0.07). The reduction of immunosuppression, thereafter, may go along with successive blood pressure reduction and the need to modify antihypertensive medication until the long-term immunosuppressive regimen is established. In the present study population, both long-term and 12-month blood pressure variability are not associated with the cumulative endpoint. It is unlikely that the observed lacking association of blood pressure variability and survival is the consequence F I G U R E 3 Cox regression curves (adjusted for age, gender, BMI, and coronary heart disease) for the endpoint (A) death and (B) graft loss. Survival over the 120 mo follow-up period in dependence of systolic blood pressure (BP), systolic blood pressure variability as measured by the coefficient of variation (CV) and pulse pressure. Analysis was performed for two groups based on the median value of the parameter (BP, CV, pulse pressure) over the first 12 mo after transplantation of an insufficient study power, since blood pressure itself proved to have a substantial impact on the composite endpoint. After ten years of follow-up, patient and graft survival was 68% in those with a systolic blood pressure lower than median compared to 51% with a blood pressure higher than the median.
| D ISCUSS I ON
The association of blood pressure and graft survival has been repeatedly demonstrated in the literature. For example, the Collaborative Transplant Study (CTS) revealed a "the lower the better" relationship down to a systolic blood pressure of 120 mm Hg. 19 Beyond its impact on graft survival, blood pressure has previously demonstrated to affect mortality after kidney transplantation. 9 Analogously, a lower systolic blood pressure proved to be associated with better patient survival (P = 0.02) and showed a strong trend for a better graft survival in the individual Cox analyses (P = 0.06). The
Systolic Blood Pressure Intervention Trial (SPRINT) recently demonstrated that subjects at high cardiovascular risk benefit from a more intense blood pressure control. 20 A targeted systolic blood pressure <120 mm Hg went along with a 27% reduction of overall and a 42% reduction of cardiovascular mortality than a blood pressure goal <140 mm Hg. The present data again illustrate the crucial role of blood pressure control in the prevention of cardiovascular events.
Moreover, they raise the question of the optimal target blood pressure after renal transplantation. Systolic BP but not BP variability was inversely associated with allograft function.
Pulse pressure is a marker of arterial stiffness. It is a strong and independent marker of cardiovascular risk. A 10 mm Hg increase of pulse pressure is associated with a 24% increase risk of stroke. 21 Our data show for the first time that pulse pressure reflects long-term cardiovascular risk in the transplant population as well. KaplanMeier analyses for pulse pressure within the first 12 months and over the whole follow-up period showed that a lower pulse pressure went along with a better patient and graft survival. This effect was mainly driven by the association of pulse pressure with patient survival. Not unexpected, the association was lost in the Cox regression, since here adjustment for coronary artery disease was performed. Inevitably, this arteriosclerotic disease is characterized by a high systemic arterial stiffness. The lacking association of blood pressure variability and survival was independent of adjustment for coronary artery disease.
End-stage renal disease goes along with a substantially accelerated arteriosclerosis and is associated with an excessively increased cardiovascular risk. Kidney transplantation ameliorates the risk compared to patients on the waiting list, 2 but cardiovascular morbidity and mortality remain substantially increased compared to the general population. 22, 23 This massively increased risk is based on both traditional and "nontraditional" risk factors. Traditional risk factors like hyperlipidaemia, hypertension, and diabetes are highly more prevalent in renal transplant recipients than in the general population. 24 It may be speculated that the multitude of these factors are the reason, why a single subordinate risk factor like blood pressure variability could not prove an independent impact on mortality or graft survival. Moreover, subjects with lower blood pressure variability tended to be slightly older. Noteworthy, however, a very recent work on the effect of blood pressure variability on cardiovascular outcome in the SPRINT trial suggested only a marginal association of long-term blood pressure variability and survival. 25 Our study is limited by its retrospective character, which does not allow attributing causality to any observed association.
Moreover, the study investigated just one aspect of blood pressure variability, namely the inter-visit variability. Thus, an association of posttransplant survival and, for example, diurnal variability cannot be excluded. Finally, we cannot provide data on smoking habits, which is associated both with mortality and cardiovascular events after renal transplantation. 26, 27 Strengths of the study are the long follow-up of 120 months and the quite large population of 877 subjects, which allowed detecting a clear signal for the impact of blood pressure on outcome.
The present study shows that strict blood pressure control both in the first year after transplantation and in the long-term is of crucial relevance for patient and graft survival. Moreover, it
demonstrates that a high amplitude of systolic and diastolic pressure is associated with increased risk of mortality and graft loss.
Inter-visit blood pressure variability, however, was not associated with adverse outcome.
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